Compare · AEON vs NVO
AEON vs NVO
Side-by-side comparison of AEON Biopharma Inc. (AEON) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AEON and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 10103.1x AEON ($19.0M).
- Over the past year, AEON is down 7.6% and NVO is down 44.9% - AEON leads by 37.4 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 1 for AEON).
- NVO has more recent analyst coverage (25 ratings vs 1 for AEON).
- Company
- AEON Biopharma Inc.
- Novo Nordisk A/S
- Price
- $0.82-4.75%
- $41.56-3.21%
- Market cap
- $19.0M
- $191.82B
- 1M return
- -11.07%
- -9.23%
- 1Y return
- -7.57%
- -44.92%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 1
- 8
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AEON
- AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
- AEON Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by AEON Biopharma Inc.
- AEON Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form DEFA14A filed by AEON Biopharma Inc.
- SEC Form DEF 14A filed by AEON Biopharma Inc.
- AEON Biopharma Sets Annual Shareholder Meeting
- SEC Form 4 filed by Bencich John
- SEC Form 3 filed by new insider Bencich John
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care